131 related articles for article (PubMed ID: 33132274)
1. [Protective Effect of Epalrestat against Oxidative Stress-induced Cytotoxicity].
Tatsunami R; Murao Y; Sato K
Yakugaku Zasshi; 2020; 140(11):1381-1388. PubMed ID: 33132274
[TBL] [Abstract][Full Text] [Related]
2. Epalrestat increases intracellular glutathione levels in Schwann cells through transcription regulation.
Sato K; Yama K; Murao Y; Tatsunami R; Tampo Y
Redox Biol; 2013; 2():15-21. PubMed ID: 24363998
[TBL] [Abstract][Full Text] [Related]
3. Epalrestat increases glutathione, thioredoxin, and heme oxygenase-1 by stimulating Nrf2 pathway in endothelial cells.
Yama K; Sato K; Abe N; Murao Y; Tatsunami R; Tampo Y
Redox Biol; 2015; 4():87-96. PubMed ID: 25529839
[TBL] [Abstract][Full Text] [Related]
4. Protective Effects of Novel Substituted Triazinoindole Inhibitors of Aldose Reductase and Epalrestat in Neuron-like PC12 Cells and BV2 Rodent Microglial Cells Exposed to Toxic Models of Oxidative Stress: Comparison with the Pyridoindole Antioxidant Stobadine.
Elmazoglu Z; Prnova MS; Stefek M; Ceylan AF; Aschner M; Rangel-López E; Santamaria A; Karasu C
Neurotox Res; 2021 Jun; 39(3):588-597. PubMed ID: 33713301
[TBL] [Abstract][Full Text] [Related]
5. Neuroprotective Effect of Epalrestat on Hydrogen Peroxide-Induced Neurodegeneration in SH-SY5Y Cellular Model.
Lingappa S; Shivakumar MS; Manivasagam T; Somasundaram ST; Seedevi P
J Microbiol Biotechnol; 2021 Jun; 31(6):867-874. PubMed ID: 33820886
[TBL] [Abstract][Full Text] [Related]
6. Epalrestat Upregulates Heme Oxygenase-1, Superoxide Dismutase, and Catalase in Cells of the Nervous System.
Yama K; Sato K; Murao Y; Tatsunami R; Tampo Y
Biol Pharm Bull; 2016 Sep; 39(9):1523-30. PubMed ID: 27439473
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of epalrestat mediated through oxidative stress markers, cytokines and TAU protein levels in diabetic rats.
Jaiswal S; Mishra S; Torgal SS; Shengule S
Life Sci; 2018 Aug; 207():364-371. PubMed ID: 29936149
[TBL] [Abstract][Full Text] [Related]
9. [Elucidation and Application of Novel Action of Therapeutic Agents for Diabetic Neuropathy].
Sato K
Yakugaku Zasshi; 2022; 142(10):1037-1044. PubMed ID: 36184437
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition effect of epalrestat on rat lens osmotic expansion].
Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
[TBL] [Abstract][Full Text] [Related]
12. Epalrestat Stimulated Oxidative Stress, Inflammation, and Fibrogenesis in Mouse Liver.
Le Y; Chen L; Zhang Y; Bu P; Dai G; Cheng X
Toxicol Sci; 2018 Jun; 163(2):397-408. PubMed ID: 28204799
[TBL] [Abstract][Full Text] [Related]
13. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
[TBL] [Abstract][Full Text] [Related]
14. Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity.
Nakamura J; Kasuya Y; Hamada Y; Nakashima E; Naruse K; Yasuda Y; Kato K; Hotta N
Diabetologia; 2001 Apr; 44(4):480-7. PubMed ID: 11357479
[TBL] [Abstract][Full Text] [Related]
15. Ischemic postconditioning during reperfusion attenuates oxidative stress and intestinal mucosal apoptosis induced by intestinal ischemia/reperfusion via aldose reductase.
Wen SH; Ling YH; Li Y; Li C; Liu JX; Li YS; Yao X; Xia ZQ; Liu KX
Surgery; 2013 Apr; 153(4):555-64. PubMed ID: 23218881
[TBL] [Abstract][Full Text] [Related]
16. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
[TBL] [Abstract][Full Text] [Related]
18. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
[TBL] [Abstract][Full Text] [Related]
19. Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats.
Yang BB; Hong ZW; Zhang Z; Yu W; Song T; Zhu LL; Jiang HS; Chen GT; Chen Y; Dai YT
Int J Impot Res; 2019 Mar; 31(2):97-104. PubMed ID: 30214006
[TBL] [Abstract][Full Text] [Related]
20. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
